Clinical Trials
25 trialsNCT07217171 2026-06-03
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
EvolveImmune United, Inc
Phase 1 Recruiting
NCT06270706 2026-04-20
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
Phase 1 Recruiting
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
NCT05544929 2026-01-06
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Phase 1 Active not recruiting
NCT04272034 2025-10-16
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
Phase 1 Terminated
NCT04328740 2025-05-01
Phase 1 Study of Oral TP-1454
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT03894618 2025-04-02
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
Shattuck Labs, Inc.
Phase 1 Completed
NCT05578820 2024-07-01
Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid
Gene Surgery LLC
Phase 1 Completed
NCT05518201 2024-04-17
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Completed
NCT06358053 2024-04-10
CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers
Corregene Biotechnology Co., Ltd
Phase 1 Not yet recruiting
NCT05787535 2024-02-02
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
HRYZ Biotech Co.
Phase 1 Unknown
NCT05952947 2024-02-02
HRYZ-T101 Injection for HPV18 Positive Solid Tumor
HRYZ Biotech Co.
Phase 1 Recruiting
NCT03849469 2023-03-30
DUET-4
Xencor, Inc.
Phase 1 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT04672980 2022-12-08
RTX-321 Monotherapy in Patients With HPV 16+ Tumors
Rubius Therapeutics
Phase 1 Terminated
NCT03517488 2022-12-01
DUET-2
Xencor, Inc.
Phase 1 Completed
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT05122221 2022-06-28
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
Phase 1 Unknown
NCT03677960 2019-07-24
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
Phase 1 Terminated
NCT03202992 2019-02-07
Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection
Antiva Biosciences
Phase 1 Completed
NCT02526316 2017-07-02
VICORYX-2
Oryx GmbH & Co. KG
Phase 1 Completed
NCT01115790 2016-05-10
A Phase 1 Study in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00423254 2010-08-03
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation
Phase 1 Completed
NCT00028405 2005-06-24
Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors
Light Sciences LLC
Phase 1 Completed